Four-Year Outcomes by Donor Type from the Long-Term Extension of the Belatacept BENEFIT and BENEFIT-EXT Studies

被引：0

作者：

Durrbach, A. ^{[1
]}

Medina Pestana, J. ^{[2
]}

Becker, T. ^{[3
]}

Grinyo, J. ^{[4
]}

Lang, P. ^{[5
]}

Garcia, V. D. ^{[6
]}

Agarwal, M. ^{[7
]}

Duan, T. ^{[7
]}

Florman, S. ^{[8
]}

机构：

[1] Hop Kremlin Bicetre, Paris, France

[2] Hosp Rim & Hipertensao, Sao Paulo, Brazil

[3] Hannover Med Sch, Hannover, Germany

[4] Univ Hosp Bellvitge, Barcelona, Spain

[5] Hop Henri Mondor, Creteil, France

[6] Hosp Dom Vicente Scherer, Porto Alegre, RS, Brazil

[7] Bristol Myers Squibb, Princeton, NJ USA

[8] Mt Sinai Med Ctr, New York, NY 10029 USA

来源：

TRANSPLANTATION | 2012年 / 94卷 / 10期

关键词：

D O I：

10.1097/00007890-201211271-01950

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

1312

引用

页码：987 / 987

页数：1

共 50 条

[41] EVALUATION OF DONOR-SPECIFIC ANTIBODIES THROUGH 7 YEARS WITH BELATACEPT: FINAL RESULTS FROM BENEFIT-EXT
Meier-Kriesche, Herwig-Ulf
Bray, Robert
Gebel, Howard
Townsend, Robert
Larsen, Christian
TRANSPLANT INTERNATIONAL, 2015, 28 : 82 - 82
[42] IMPACT OF DONOR AGE ON 3-YEAR OUTCOMES OF EXTENDED CRITERIA DONOR KIDNEY RECIPIENTS IN BENEFIT-EXT
Lehner, Frank
Budde, Klemens M. D.
Morales, Jose M.
Blancho, Gilles
Muehlbacher, Ferdinand
Rice, Kim
Pupim, Lara
Aigner, Sigrid
Vincenti, Flavio
TRANSPLANT INTERNATIONAL, 2013, 26 : 92 - 92
[43] BELATACEPT COMPARED WITH CYCLOSPORINE IN RENAL ALLOGRAFT RECIPIENTS OF EXTENDED CRITERIA DONOR KIDNEYS: 3-YEAR OUTCOMES FROM THE PHASE III BENEFIT-EXT TRIAL
Medina Pestana, Jose O.
Grinyo, Josep M.
Vanrenterghem, Yves
Becker, Thomas
Florman, Sander
Lang, Philippe
Rial, Maria del C.
Schnitzler, Mark A.
Duan, Tao
Block, Alan
Durrbachll, Antoine
TRANSPLANT INTERNATIONAL, 2011, 24 : 68 - 68
[44] Outcomes at 3 Years in EBV plus European Subpopulations From BENEFIT and BENEFIT-EXT
Blancho, G.
Budde, K.
Merville, P.
Moal, M.
Rostaing, L.
Harler, M.
Grinyo, J.
TRANSPLANTATION, 2014, 98 : 455 - 455
[45] BELATACEPT COMPARED WITH CYCLOSPORINE IN RENAL ALLOGRAFT RECIPIENTS OF EXTENDED CRITERIA DONOR KIDNEYS: 3-YEAR OUTCOMES FROM THE PHASE III BENEFIT-EXT TRIAL
Medina Pestana, J.
Grinyo, J.
Vanrenterghem, Y.
Becker, T.
Florman, S.
Lang, P.
Rial, M. del C.
Schnitzler, M.
Duan, T.
Block, A.
Durrbach, A.
TRANSPLANT INTERNATIONAL, 2011, 24 : 51 - 51
[46] Final Results from the BENEFIT-EXT Trial: A 7 Year Follow-Up of Belatacept Treated Patients
Florman, S.
Pestana, J. Medina
Rial, M.
Rostaing, L.
Kuypers, D.
Muehlbacher, F.
Polinsky, M.
Meier-Kriesche, U.
Grinyo, J.
Durrbach, A.
AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
[47] Outcomes at 3 Years in EBV plus European Subpopulations From BENEFIT and BENEFIT-EXT
Blancho, G.
Budde, K.
Merville, P.
Moal, M.
Rostaing, L.
Harler, M.
Grinyo, J.
AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 455 - 455
[48] OUTCOMES AT 3 YEARS IN EBV plus EUROPEAN SUBPOPULATIONS FROM BENEFIT AND BENEFIT-EXT
Budde, K.
Blancho, G.
Merville, P.
Moal, M. -C.
Rostaing, L.
Harler, M. B.
Grinyo, J.
TRANSPLANT INTERNATIONAL, 2014, 27 : 33 - 33
[49] Impact of Donor Age on Three-Year Outcomes in Recipients of Extended Criteria Kidneys Treated with Belatacept vs Cyclosporine in BENEFIT-EXT Trial.
Budde, K.
Morales, J.
Blancho, G.
Muehlbacher, F.
Lehner, F.
Rice, K.
Pupim, L.
Aigner, S.
Vincenti, F.
AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 182 - 183
[50] Belatacept Compared with Cyclosporine in Renal Allograft Recipients of Extended Criteria Donor Kidneys: 3-Year Outcomes from the Phase III BENEFIT-EXT Trial.
Medina Pestana, J.
Grinyo, J.
Vanrenterghem, Y.
Becker, T.
Florman, S.
Lang, P.
Rial, M. del C.
Schnitzler, M.
Duan, T.
Block, A.
Durrbach, A.
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 349 - 349

← 1 2 3 4 5 →